Broadening routine clinical tissue NGS panels, for example, with the frequently mutated TP53 and STK11 genes, will increase the number of patients who can be effectively monitored for tumor response using plasma ccfDNA with single‐gene approaches such as ddPCR. The gene discussed is TP53; the disease is neoplasm.